TP53 and cancer: Compound 1 showed selective in vitro anti-cancer activity against M14 and A375 melanoma cell lines and a synergistic effect when used in combination with nutlin-3a indicating that they do not compete for the same binding site but rather hit the same molecular pathway, such as the p53 pathway, reducing p53-MDM2 complex formation [11,12].